Dr Edwin Moses appointed as Chairman of the Board of Sensorin
Moses joins from his previous role as Chief Executive Officer of Ablynx and brings 25 years of experience at the top level of life science companies. He was in his role at Ablynx for 14 years and drove its growth, which led to it being acquired by Sanofi in 2018.
Nawal Ouzren, CEO of Sensorion said: “I would also like to extend my gratitude to Patrick Langlois for his dedicated service as Chairman of Sensorion over the last five years. Patrick’s knowledge and expertise have been important factors guiding the Company to this important transition. He leaves us in a strong position, and we wish him all the best for the future.”
“We are honored and delighted to welcome Edwin as Chairman of Sensorion. He brings invaluable experience in all elements of leadership in the biotech industry, from research and clinical development to financing, regulatory approval, partnering and M&A. His appointment further strengthens our leadership team and will add momentum to the development of our expanding hearing loss pipeline, including gene therapy for monogenic forms of hearing loss, as well as the clinical development of our lead product SENS-401 to treat sudden sensorineural hearing loss, for which we expect to report top-line Phase 2 clinical data in mid-2021.”
Previously, Moses led the growth of Oxford Asymmetry International as CEO and Chairman between 1993 and 2001. He is also currently the Chairman of Achilles Therapeutics, Avantium NV and LabGenius Ltd, and is an Operating Partner at Keensight Capital.
Commenting on his appointment, Moses said: “Sensorion’s lead program SENS-401, in Phase 2 clinical testing, has promising potential to treat sudden sensorineural hearing loss, including that commonly experienced by soldiers after auditory trauma, as well as other forms of hearing loss. Additionally, the notable partnership with Institut Pasteur, to discover and develop a wide range of gene therapies for rare hearing disorders, may help many people who currently have no satisfactory therapeutic options.
“I am truly excited to be taking on the role of Chairman at such an important time in the development of Sensorion and look forward to joining the exceptional scientific and business team supporting the Company on this exciting journey.
